The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants. bioRxiv [Preprint]. 2021 Apr 8:2021.04.08.438884. Source link: [link].

Protein 52

Protein Vaccination Vaccine Antibody 52

pharmaphorum

DECEMBER 1, 2022

Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Etienne De Braekeleer, Senior Research Scientist, AstraZeneca.

In-Vitro 52

In-Vitro Scientist Engineer Gene Therapy 52

pharmaphorum

MARCH 1, 2021

COVID-19 antigen tests diagnose active infection by detecting SARS-CoV-2 viral proteins in samples, as opposed to PCR tests which detect viral RNA and require lab processing, but can miss infections with low virus levels. The test – which can also be self-collected – showed a sensitivity of 93.8%

In-Vitro 98

In-Vitro RNA Protein Antibody 98

XTalks

APRIL 22, 2022

Both the areas of drug development and clinical trials are increasingly using in vitro assays to help determine the efficacy of an investigational therapeutic. Flow cytometric receptor occupancy assays are being increasingly used in preclinical and clinical studies. What is Flow Cytometry?

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

APRIL 6, 2022

Scientists at the University of Cambridge evaluated the use of a personalized blood test that detects ctDNA to help predict the relapse risk of lung cancer. Register for this webinar to get an overview of the role of long non-protein coding RNAs (lncRNAs) in gene regulations. Photo source: Inivata.

DNA 105

DNA In-Vitro Doctor Doctors 105

pharmaphorum

JANUARY 18, 2022

Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Key Benefits of Attending: • Discuss the uses of advanced cell technologies to construct in vitro models of human tissues. Academia Professor – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering.

In-Vitro 52

In-Vitro Engineer Drugs Pharma Companies 52

The Pharma Data

FEBRUARY 25, 2022

Several FDA-approved drugs – including for type 2 diabetes, hepatitis C and HIV – significantly reduce the ability of the Delta variant of SARS-CoV-2 to replicate in human cells, according to new research led by scientists at Penn State. ” The findings published today (Feb. 25) in the journal Communications Biology. .

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

XTalks

JANUARY 21, 2022

With the Omicron variant of SARS-CoV-2 continuing to run rampant, Italian in vitro diagnostics (IVD) company A.Menarini Diagnostics has unveiled a new real-time (RT)-PCR-based test that can detect several variants of the coronavirus including Omicron and Delta. We are extremely proud to have made this unique solution available so quickly.

RNA 69

RNA In-Vitro Protein Gene 69

pharmaphorum

NOVEMBER 4, 2020

However, in vitro or binding-based efficacy insight needs to be confirmed by reliable clinical evidence, as shown by the outcomes of COVID-19 trials with remdesivir and hydroxychloroquine. million worldwide and continues to increase despite the global public health measures that have been put in place.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Vaccine 105

The Pharma Data

JANUARY 12, 2021

The LumiraDx SARS-CoV-2 Antigen Test uses Fast Microfluidic Immunofluorescence (FMI) technology to detect antigen nucleocapsid protein from nasal or nasopharyngeal swabs with high sensitivity results in 12 minutes. LONDON , Jan. Test specificity was 99.5% in nasal swab specimens. in nasal samples and 97.8% in nasopharyngeal samples.

In-Vitro 52

In-Vitro Protein Scientist Manufacturing 52

XTalks

MARCH 11, 2021

As a novel virus, public health experts, scientists and clinicians faced challenges in how to effectively prevent its transmission, and how to best treat it in the most severe cases. After its identification in late 2019, COVID-19 was officially declared a pandemic by the World Health Organization (WHO) on March 11, 2020. COVID-19 Treatments.

Vaccination 98

Vaccination Vaccine In-Vitro Antibody 98

The Pharma Data

DECEMBER 20, 2020

Klisyri is a home-grown product discovered and characterized by Athenex scientists and developed from pre-IND to NDA by the Athenex team. The data supported the potential benefits of the drug for OAB in patients with urge urinary incontinence (UUI), urgency, and urinary frequency. The drug is a once-daily, beta-3 adrenergic agonist.

In-Vitro 52

In-Vitro FDA Approval Drugs Manufacturing 52

The Pharma Data

JANUARY 20, 2021

The LumiraDx SARS-CoV-2 Antigen Test is authorized for use by FDA under an Emergency Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein. The LumiraDx SARS-CoV-2 Antigen Test is authorized for use by FDA under an Emergency Use Authorization (EUA) only for the detection of SARS-CoV-2 nucleocapsid protein.

In-Vitro 52

In-Vitro Protein Scientist Manufacturing 52

The Pharma Data

NOVEMBER 1, 2020

The first shipment of 1.2 million SARS-CoV-2 Assays for use on the BD Veritor Plus System to be delivered in The Netherlands by mid-November. THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J. , THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J. , The first 1.2 million units will be delivered by mid-November. Food and Drug Administration (FDA).

In-Vitro 52

In-Vitro Production Protein Scientist 52

The Pharma Data

MARCH 16, 2021

This research use only laboratory test can be used to help scientists track mutation prevalence and to assess any potential impact on diagnostics, vaccines and therapeutics, providing crucial insight for healthcare systems in making appropriate measures to combat COVID-19. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). 1.351 and P.1

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccine 52

The Pharma Data

AUGUST 18, 2020

REGN-COV2 is Regeneron’s two-antibody combination currently in late-stage clinical trials for the treatment and prevention of COVID-19 infection. The companies will collaborate on developing and manufacturing REGN-COV2. Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S. Schleifer, M.D.,

Antibody 52

Antibody Clinical Trials Clinical Trials Manufacturing 52

Roots Analysis

OCTOBER 19, 2023

Bacteria plays a crucial role in maintaining the ecosystem balance. However, there are few species of bacteria that can cause several infectious diseases ( such as strep throat, salmonellosis, tuberculosis, whooping cough ). These are mainly transmitted through air, water, living organisms, and food.

Bacteria 40

Bacteria Production In-Vivo In-Vitro 40

The Pharma Data

MAY 14, 2021

It looked like a hurricane had pummeled through my closet…. Wrinkled jeans and dresses scattered in every direction…. There wasn’t a single outfit that fit me…. I swear — I went to bed a size 10 and woke up a size 16. My teenage daughter shouted at me from downstairs for the third time…. I have to be at school in 5 minutes!”. What are you doing?!

Hormones 52

Hormones Production Doctor Doctors 52

Pharmaceutical Technology

FEBRUARY 23, 2023

Our chemists and formulation scientists review the properties of new drug candidates and “work their magic” to develop formulations that improve the exposure profile of the compound. Quotient Sciences helps biotech and pharma customers in the development and optimization of drug products.

Development 246

Development Drugs Bioavailability In-Vivo 246

XTalks

NOVEMBER 20, 2020

A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test. The cell-based tests are designed to identify specific T cells that are activated in response to a pathogen — which in this case would be SARS-CoV-2.

Antibody 98

Antibody Immune Response Protein In-Vitro 98

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus. The price of that prize is incalculable.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92